Biotech re­ceives award from DOD; Reg­u­la­tors ac­cept Ap­pili Ther­a­peu­tic­s' NDA

Eu­Men­tis Ther­a­peu­tics, a Boston-based biotech, has been hand­ed an award from the US De­part­ment of De­fense.

The $3 mil­lion award will be used by Eu­Men­tis to work on a small mol­e­cule for trau­mat­ic brain in­jury that aims to tar­get the N-methyl-D-as­par­tate re­cep­tor. Specif­i­cal­ly, the biotech will study three an­tag­o­nists to eval­u­ate TBI in an an­i­mal study this year. That study will be done in col­lab­o­ra­tion with a pro­fes­sor at the Uni­ver­si­ty of Penn­syl­va­nia.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.